Prostate cancer
Early detection, diagnosis, and advances in treatment- Review of updated data for healthcare providers
Bibliographic Data
Background: Prostate cancer (PCa) is the most commonly diagnosed cancer among men in the U.S. and the second leading cause of cancer-related deaths. Standard treatment options include radical prostatectomy and radiation for localized PCa, while androgen ablation therapy is used for recurrent or advanced stages. However, almost all patients progress to metastatic castration-resistant prostate cancer (mCRPC), with limited treatment options that offer only modest survival improvements. Immunotherapy has shown promise in addressing this challenge. Aim: This review aims to discuss the current advancements in the early detection, diagnosis, and treatment of PCa, with a focus on immunotherapy and ongoing clinical trials. Methods: A comprehensive literature review was conducted to analyze data from recent clinical trials, focusing on the efficacy of current treatments such as vaccines, immune checkpoint inhibitors (ICIs), cell-based therapies, and DNA-based immunotherapy approaches. Various ongoing clinical trials in the field were also reviewed. Results: Current FDA-approved treatments for mCRPC, such as docetaxel, abiraterone, and Sipuleucel-T, have shown survival advantages of 2-4 months. Immunotherapeutic approaches, including Sipuleucel-T, have demonstrated improved overall survival in clinical trials. Numerous ongoing trials are investigating new combinations of immunotherapies, vaccines, and immune modulators to enhance treatment efficacy
Cancer · Health care · Intensive care medicine · Medical physics · Prostate cancer · Hepatitis B Virus Studies · Medicine · Prostate Cancer Diagnosis and Treatment · Prostate Cancer Treatment and Research · Internal Medicine · Oncology
| Highly cited | No |
|---|